Latest news from all over the world

Work is done in a laboratory at the Gamale Institute in Moscow, where a Kovid-19 vaccine is being developed. Vyacheslav Prokofiev / TASS / Getty Images

The Russian Direct Investment Fund (RDIF) and the Brazilian state of Bahia have signed a cooperation agreement to supply 50 million doses of the Russian vaccine Sputnik-V.

Deliveries are expected to begin in November 2020, subject to approval by Brazilian regulators with consideration of the results of post-delivery testing.

The Russian Direct Investment Fund (RDIF) said in a statement on Friday, the agreement reached through the state’s Health Secretariat, will enable future parties to distribute the vaccine in Brazil.

“The Government of the State of Bahia in Brazil is very pleased with the agreement signed with the Sovereign Wealth Fund of the Russian Federation, which will guarantee access to the Sputnik V vaccine for Brazilians, as soon as it is approved” Brazilian National Regulatory authorities, ”Bahia State Health Secretary, Dr. Fabio Vilas-Bose Pinto said in a statement released by RDIF.

“As it is a vaccine created using human adenoviruses, one of the safest and effective vaccine development platforms in the world, we believe that the results of ongoing Phase 3 clinical trials are in phase 1 and 2 Will confirm the figures gone. “She added.

RDIF told CNN that they hope to announce the supply of tens of millions of Sputnik-Vs to other countries around the world in the coming times.

Here is some background: Russia was criticized when it announced the world’s first approved coronavirus vaccine for public use in August – even before the critical Phase 3 trial had been completed.

Results from the Phase I and 2 studies of the vaccine, published in The Lancet Medical Journal, showed that the vaccine neutralized antibodies in dozens of study subjects.

According to the study, the vaccine neutralized antibodies in dozens of subjects studied, and while it often produced side effects such as fever, those side effects were mostly mild.

Scientists not involved in the study said that, while the results are a positive sign, only larger, phase 3 trials can confirm whether the vaccine actually prevents disease with Kovid-19.

According to Kirill Dimryk, head of the Russian Direct Investment Fund (RDIF), researchers are already distributing the vaccine to high-risk groups, which is financing Russian vaccine research.

Russian authorities have thrown out teachers as well as doctors – key activists who will get access to the first vaccine, even before critical phase 3 human trials have ended.